This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Ceftin

GlaxoSmithKline plc

Drug Names(s): Cefuroxime axetil

Description: Ceftin is a semisynthetic, broad-spectrum second generation cephalosporin antibiotic for oral administration. Compared to first generation cephalosporins such as Keflex, second generation cephalosporins exhibit better Gram-(-) activity and somewhat weaker Gram-(+) activity. They are more stable to Gram-(-) beta lactamases. They exhibit good activity against many enteric Gram-(-) rods, Haemophilus influenzae, and Neisseria gonorrheae; moderate activity against streptococci and staphylococci; and poor activity against enterococci, methacillin resistant Staphylococcus aureus and Psuedomonas.

As with all cephalosporins, Ceftin inhibits bacterial cell wall synthesis by inhibiting penicillin binding proteins.


Ceftin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug